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OBJECTIVES: Results from the HERA, NSABP B-31, and
NCCTG N9831 trails demonstrated a reduction in risk of recur-
rence by approximately 50% with the addition of trastuzumab to
standard adjuvant therapy in early breast cancer (EBC). The
objective of this cost-effectiveness analysis (CEA) is to evaluate
the long term clinical outcomes and economic impact of one year
adjuvant trastuzumab compared to no trastuzumab in addition
to standard adjuvant therapy for patients with HER2-positive
EBC in Taiwan from the payer’s [Bureau of National Health
Insurance (BNHI)] perspective. METHODS: A ﬁve-state Markov
model was developed to estimate the incremental cost and long-
term health outcomes in terms of quality-adjusted life years
(QALYs) of EBC over a patient’s lifetime. Clinical outcomes and
disease transition probabilities were derived from the HERA
trial. Direct medical costs associated with drugs, trastuzumab
administration, and HER2 testing were based on Taiwan’s
National Health Insurance fee schedule 2007. Medical resource
utilizations associated with disease free survival (DFS), recur-
rence, metastasis, and cardiac side effects were estimated by
an expert panel survey conducted among ten oncologists.
Population-based utilities were applied to the main health states
in the Markov model, while disutilities of cardiac events were
obtained from published literature. Beneﬁts and future costs were
discounted at annual rate of 3.5%. One-way sensitivity analyses
were performed on key model parameters. RESULTS: Compared
to standard adjuvant therapy alone, adding trastuzumab to stan-
dard treatment increased drugs costs and DFS, however, the
incremental costs were offset by reduced costs of recurrence and
metastasis. Over a lifetime, one year adjuvant trastuzumab
yielded an incremental cost-effectiveness ratio (ICER) of
NTD$152,620 (€3,451) per QALY. Adjuvant trastuzumab
remained cost-effective under sensitivity testing. CONCLU-
SION: From the perspective of Taiwan BNHI, this CEA demon-
strates that one year adjuvant trastuzumab offers health beneﬁts
at a favorable ICER in patients with HER2-positive EBC.
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OBJECTIVES: In 2007 trastuzumab (T) received regulatory
approval in Brazil for 1 year treatment of HER2-positive patients
with early breast cancer (eBC) in addition to standard chemo-
therapy. The objective of this analysis is to estimate cost-
effectiveness of T in eBC from the private third-party payer
perspective. METHODS: A Markov state transition model was
designed to capture the natural history and course of disease for
early stage breast cancer patients, and to simulate cost and
disease progression over a life time perspective. Disease transi-
tion probabilities and clinical outcomes were derived from the
HERA trial. Direct costs were considered to estimate the incre-
mental cost-effectiveness ratio using both quality-adjusted life
years (QALYs) and life years gained (LYGs). A local Delphi panel
was conducted to reﬂect local clinical practice and assess medical
care utilization (for disease-free survival, loco-regional recur-
rence, metastasis, and cardiac side effects). Unit costs were based
on published sources (drugs and materials national prices list and
medical society fees list). Utilities and disutilities were obtained
from published literature. The discount rate of 3% was adopted
for both health outcomes and costs. Both one-way and probabi-
listic sensitivity analysis were performed to verify the robustness
of the results. RESULTS: T treatment costs were higher in com-
parison with standard treatment, showing higher acquisition
drug costs (R$ 190,554) and administration costs (R$ 2,160).
On the other hand, cost-offsets for R$ 168,331 were estimated
due to the reduction of the metastatic and recurrence cases. T
treatment showed an increase in LYG (1.74) and QALYs (1.80).
The estimated ICER was R$ 22,587 per QALY gained. CON-
CLUSION: From a third-party payer, this analysis suggests that
trastuzumab treatment for HER-2 positive patients with early
breast cancer is a cost-effective alternative in Brazil.
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OBJECTIVES: In an ongoing, phase III trial, sunitinib was sig-
niﬁcantly superior to IFN-a in ﬁrst-line therapy of mRCC;
(median progression-free survival [PFS] = 11 months [95% CI:
10–12] vs. 4 months [95% CI: 4–6]; P < 0.000001). This study
investigated the cost-effectiveness of sunitinib vs. IFN-a in this
setting from a US third-party payer perspective. METHODS: A
Markov model with a 10-year time horizon projected survival
and costs in 6-week cycles based on extrapolated trial survival
data. First- and second-line treatment and palliative care were
examined. The endpoints used to value model outcomes were
PFS; overall survival (OS); quality of life; adverse events (AEs)
and related dose reductions or cycle interruptions. Progression-
free months (PFM), life-years (LY) gained and quality adjusted
life-years (QALYs) gained were used to assess treatment efﬁcacy.
Costs incurred included those associated with physician visits,
hospitalisation, tests, scans, drugs, monitoring and treatment of
AEs. Costs (adjusted to 2006 US dollars) and survival beneﬁts
were discounted annually at 5% and sensitivity analyses (sce-
nario and probabilistic) were conducted. Results were presented
as incremental cost-effectiveness ratios (ICERs) and incremental
cost-utility ratios (ICURs). RESULTS: Longer projected PFS and
OS were obtained for sunitinib than for IFN-a. The ICERs of
sunitinib vs. IFN-a over 10-years were $1,551/PFM, $67,215/LY
and $52,593/QALY gained. Based on the probabilistic sensitivity
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analysis, sunitinib has a 45.9% and a 64.9% probability of being
cost-effective compared with IFN-a at the threshold of $50,000
and $100,000/QALY, respectively. Survival, sunitinib drug costs
and cost of best supportive care were the key drivers of the
model. CONCLUSION: Sunitinib is a cost-effective alternative
to IFN-a as ﬁrst-line treatment in mRCC, with cost-effectiveness
ratios within the established threshold that society is willing to
pay for health beneﬁts (i.e. $50,000–100,000/LY or QALY).
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OBJECTIVE: Chemotherapy-induced anemia (CIA) is often
treated with erythropoiesis-stimulating agents (ESAs). This study
assessed the cost consequence of Q3W_DA administration
(500 mg) compared to QW_EA or QW_EB from a German soci-
etal perspective.METHOD:Adecision-treemodel was developed
in MSExcel based on the results of a European retrospective
observational study that included data from 786 patients with
non-myeloid malignancy and CIA over a 16-week period. Tran-
sition probabilities, average hemoglobin (Hb) value over treat-
ment period, number of blood transfusions, drug administrations,
transfusion, response to treatment and ESA administration set-
tings were used. Unit costs were applied to medical resources used
and to patients’ time, further speciﬁed by a panel of 11 German
clinical experts. Time was valued at gross hourly wage rate. Both
time andmedical costs were extracted from ofﬁcial sources (EBM)
and adjusted to 2006€. A 5000-replications probabilistic sensitiv-
ity analysis was performed with @RISK® using distributions for
probabilities (binomial), medical resources used (normal), time
(normal) and outcome measures (normal). RESULTS: The differ-
ence in hemoglobin between treatments was: Q3W_DA minus
QW_EA, 0.13 g/dL (95%CI:-0.151, 0.420) andQ3W_DAminus
QW_EB, 0.19 g/dL (95%CI:-0.0168, 0.393). Q3W_DA resulted
in comparable mean Hb-change over time to QW_EA and
QW_EB. Lower costs were observed for Q3W_DA: -197€
[95%CI:-972, 572] vs. QW_EA and -203€ [95%CI:-722, 294]
vs. QW_EB. Sensitivity analysis for Q3W_DA revealed 56% of
the replications vs. QW_EA and 75% vs. QW_EB with better Hb
values and lower costs (dominant); 25% vs. QW_EA and 21% vs.
QW_EB with higher costs and better Hb values. CONCLU-
SIONS: This analysis with real-life information showed that
treatment of CIAwithQ_3WDAwas effective and less costly than
QW_EA and QW_EB. A decision in favor of Q3W_DA has the
highest probability to be beneﬁcial from the German societal
perspective.
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OBJECTIVES: To estimate the cost-effectiveness of cetuximab in
combination with radiotherapy (ERT) compared to radiotherapy
alone (RT), for the treatment of locally advanced head and neck
cancer in patients for whom chemoradiotherapy is inappropriate
or intolerable in the UK. METHODS: A modelled economic
evaluation calculated the incremental cost per quality-adjusted
life year (QALYs) gained with ERT compared to RT. Resource
utilisation and survival data were extracted from an international
phase-III trial of ERT. Assumptions regarding costs of care were
drawn from estimates by an expert clinical panel. Overall sur-
vival and progression-free survival times were extrapolated
beyond the trial period using statistical models. Patient survival
was stratiﬁed into health states deﬁned by adverse event status in
the acute phase and disease status post-treatment. Utility values
for the health states were obtained from a survey of oncology
nurses using the EQ-5D. Estimates of individual costs and out-
comes were estimated for each patient in the trial and overall
mean values calculated for the incremental analysis between the
treatment groups. The analysis was conducted from the perspec-
tive of the NHS. Costs and outcomes were discounted at 3.5%.
RESULTS: In the lifetime analysis, ERT patients were estimated
to gain an extra 1.26 QALYs compared to RT patients. From the
public establishment perspective, this translated into an incre-
mental cost per QALY gained of 6,390. Shortening the analysis
to the timeframe of the clinical trial (5 years) raised the ICERs to
19,951 per QALY gained respectively. Bootstrap simulation
and sensitivity analysis showed that the ICERs were robust to
changes in the key variables. CONCLUSION: Results of the
modelled economic evaluation strongly suggest that ERT offers a
good value-for-money alternative in the treatment of locally
advanced head and neck cancer in the UK.
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OBJECTIVES: Bladder cancer is the ﬁfth leading type of cancer
diagnosed in Belgium. Early detection is key in improving sur-
vival. Hexvix, by inducing tumor ﬂuorescence during cys-
toscopies, improves lesion detection, delineation and therefore
also lesion resection. The cost-effectiveness of adding Hexvix to
standard white light cystoscopy in the diagnosis and manage-
ment of non-muscle invasive bladder cancer was assessed from
the Belgian health care payers’ perspective. METHODS: A
Markov model with a 10 year time horizon, describing manage-
ment patterns and resulting outcomes in patients with suspected
bladder cancer, was developed in Excel. Treatment patterns and
clinical evolution of high (HR), medium (MR) and low (LR) risk
patients were derived from European treatment guidelines and
further validated by a panel of 3 Belgian urologists. By using
Hexvix in diagnostic cystoscopies bladder cancer could poten-
tially be detected at an earlier stage (4% HR diagnosed in MR
and 4% MR in LR) and resection could be more complete
resulting in lower recurrence rates (HR: -50%; MR: -40% and
LR: -30%; based on data obtained with an unlicensed, less
readily taken up ﬂuorescent molecule). Ofﬁcial tariffs were
applied to medical resources identiﬁed. An annual discount rate
of 3% for future cost and 1.5% for effects was applied. Results
were expressed as cost per life year gained (LYG). RESULTS:
Using this model, compared to standard white light cystoscopy
adding Hexvix, in diagnostic and therapeutic cystoscopies,
increased survival per patient could be 0.09 years at an incre-
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